EMA recommends Pfizer/BioNTech vaccine for use in EU

Science

Image by Shutterstock.com

The European Medicines Agency (EMA) recommended on Monday that a vaccine jointly developed by Pfizer and BioNTech against the COVID-19 coronavirus should be made commercially available in the European Union, according to a report by state news wire MTI.

The agency has reached its decision in an accelerated procedure that gives the green light to the conditional use of the vaccine for one year.

The marketing is formally authorized by the European Commission, which is expected to announce its approval shortly.

Speaking at a regular press briefing on Monday, Hungary's Chief Medical Officer Dr. Cecília Müller said the immunization of healthcare workers in the country could start several days after EMA's approval, adding that first "token" delivery would be of enough doses for almost 5,000 people. More shipments of the vaccine will follow before year-end, and deliveries will arrive on a continuous basis later, she added.

Hungary has pre-ordered 4.4 million doses of the Pfizer vaccine.

ADVERTISEMENT

Business, consumer confidence improves - Századvég Analysis

Business, consumer confidence improves - Századvég

Opposition parties to begin PM candidate primaries Elections

Opposition parties to begin PM candidate primaries

New managing director at the helm of Wolt Hungary Appointments

New managing director at the helm of Wolt Hungary

Budapest bike-sharing scheme boasts record ridership City

Budapest bike-sharing scheme boasts record ridership

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.